|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1996-6-4
|
|
pubmed:abstractText |
In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-alpha2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-1203882,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-1996557,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-1998599,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-2452861,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-2562921,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-3124442,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-3207601,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-3516252,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-3691759,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-3717812,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-3838922,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-3896288,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-4653931,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-476303,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-57335,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-6200220,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-6362819,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-6697291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-698913,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-7903690,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8611382-7981078
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Melphalan,
http://linkedlifedata.com/resource/pubmed/chemical/Peptichemio,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
pubmed-author:AscariEE,
pubmed-author:BarbaranoLL,
pubmed-author:BergonziCC,
pubmed-author:BrugnatelliSS,
pubmed-author:De PaoliAA,
pubmed-author:Di StasiMM,
pubmed-author:MoriGG,
pubmed-author:PetriniMM,
pubmed-author:PiccininoFF,
pubmed-author:PivaNN,
pubmed-author:RiccardiAA,
pubmed-author:RinaldiEE,
pubmed-author:TrottaOO,
pubmed-author:WebbP MPM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
794-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8611382-Adult,
pubmed-meshheading:8611382-Aged,
pubmed-meshheading:8611382-Antineoplastic Agents, Alkylating,
pubmed-meshheading:8611382-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8611382-Cyclophosphamide,
pubmed-meshheading:8611382-Drug Administration Schedule,
pubmed-meshheading:8611382-Epirubicin,
pubmed-meshheading:8611382-Female,
pubmed-meshheading:8611382-Humans,
pubmed-meshheading:8611382-Interferon-alpha,
pubmed-meshheading:8611382-Male,
pubmed-meshheading:8611382-Melphalan,
pubmed-meshheading:8611382-Middle Aged,
pubmed-meshheading:8611382-Multiple Myeloma,
pubmed-meshheading:8611382-Myeloproliferative Disorders,
pubmed-meshheading:8611382-Peptichemio,
pubmed-meshheading:8611382-Prednisone,
pubmed-meshheading:8611382-Recombinant Proteins,
pubmed-meshheading:8611382-Vincristine
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
|
|
pubmed:affiliation |
Medicina Interna ed Oncologia Medica, Universita and Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
